Danaher Corporation (NYSE:DHR) Given Consensus Rating of “Moderate Buy” by Analysts

Danaher Corporation (NYSE:DHR) has been assigned a consensus recommendation of “Moderate Buy” from the twenty ratings firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and seventeen have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $243.20.

A number of equities analysts have recently commented on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Wolfe Research reduced their price objective on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. UBS Group reduced their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Danaher in a report on Wednesday.

Insider Transactions at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Danaher

Several institutional investors have recently added to or reduced their stakes in DHR. Sivia Capital Partners LLC lifted its holdings in Danaher by 6.3% during the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after purchasing an additional 119 shares during the last quarter. First Trust Advisors LP lifted its holdings in Danaher by 34.5% during the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares during the last quarter. Main Street Financial Solutions LLC lifted its holdings in Danaher by 40.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after purchasing an additional 886 shares during the last quarter. Ieq Capital LLC lifted its holdings in Danaher by 64.2% during the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after purchasing an additional 29,592 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Danaher by 30.7% during the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock valued at $273,000 after purchasing an additional 325 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

NYSE:DHR opened at $184.11 on Friday. The company has a 50-day moving average of $197.17 and a 200-day moving average of $214.35. The company has a market capitalization of $130.30 billion, a price-to-earnings ratio of 35.61, a PEG ratio of 2.64 and a beta of 0.95. Danaher has a 52 week low of $180.03 and a 52 week high of $242.80. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.96%. The firm’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period last year, the firm earned $1.88 EPS. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, equities research analysts anticipate that Danaher will post 8.39 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $1.60 annualized dividend and a yield of 0.9%. This is an increase from Danaher’s previous quarterly dividend of $0.32. Danaher’s payout ratio is 30.95%.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and modestly higher FY outlook — Danaher reported $2.06 non?GAAP EPS (above consensus) and raised FY2026 EPS guidance to $8.35–$8.55, which supports the stock’s fundamental earnings trajectory. Danaher Reports First Quarter 2026 Results
• Positive Sentiment: Bioprocessing and Life Sciences momentum — Management cited strong demand in bioprocessing and life?sciences tools (double?digit strength in some businesses), a key driver of beat?and?raise dynamics. Reuters: Danaher beats first-quarter profit estimates
• Positive Sentiment: Some analyst support remains — Evercore raised its target to $232 (outperform), indicating pockets of continued buy?side confidence despite cuts elsewhere. Evercore raises Danaher target
• Neutral Sentiment: €2.98B senior notes offering — Danaher priced €3.0B of euro?denominated senior notes across several maturities; proceeds boost liquidity (and may fund M&A like Masimo) but add long?term debt. PR Newswire: Euro?denominated senior notes offering
• Negative Sentiment: Revenue miss and Diagnostics softness — Revenue rose ~3.7% to $5.95B, below consensus; core revenue growth was modest and Diagnostics (Cepheid/respiratory) was a clear weak spot, which pressured sentiment despite the EPS beat. Yahoo Finance deep dive
• Negative Sentiment: Multiple price?target cuts — Several firms trimmed targets (JPMorgan, UBS, Guggenheim, Wells Fargo, TD Cowen among others), amplifying near?term selling pressure even though many retain buy/overweight stances. MarketScreener: JPMorgan target change
• Negative Sentiment: Acquisition/integration and insider selling concerns — Investors are parsing the planned Masimo acquisition and near?term capital allocation; recent insider sales headlines add to the cautious tone. QuiverQuant analysis

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.